Lezyncet A Tablet is a combination medication containing Levocetirizine 2.5 mg and Ambroxol 60 mg, formulated to provide effective relief from allergic respiratory conditions accompanied by mucus congestion. Levocetirizine, a third-generation non-sedative antihistamine, selectively inhibits peripheral H1 histamine receptors, thereby reducing symptoms such as sneezing, nasal itching, rhinorrhea, and ocular irritation associated with allergic rhinitis and chronic urticaria. Ambroxol acts as a mucolytic agent, enhancing the clearance of mucus by stimulating the production of serous mucus in the respiratory tract, facilitating expectoration and improving airway patency. This dual-action formulation is particularly beneficial in managing upper and lower respiratory tract disorders where allergic inflammation and mucus hypersecretion coexist, such as allergic bronchitis and post-viral cough with mucus retention. Lezyncet A is generally well-tolerated; however, patients should be advised to adhere to prescribed dosages and consult healthcare professionals if adverse effects such as drowsiness, gastrointestinal disturbances, or hypersensitivity reactions occur. It is contraindicated in individuals with known hypersensitivity to either component and should be used cautiously in patients with renal impairment. Overall, Lezyncet A Tablet offers a synergistic approach to alleviating allergic symptoms and promoting mucus clearance, thereby improving respiratory comfort and function.